Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients

Imatinib mesylate is considered the standard first-line systemic treatment for patients with chronic myeloid leukemia (CML) and functions by targeting BCR-ABL tyrosine kinases. Imatinib has substantially changed the clinical management and improved the prognosis of CML and Philadelphia chromosome-po...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yu, Qian, Si-Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949731/
https://www.ncbi.nlm.nih.gov/pubmed/24623982
http://dx.doi.org/10.2147/OTT.S38846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949731/
https://www.ncbi.nlm.nih.gov/pubmed/24623982
http://dx.doi.org/10.2147/OTT.S38846

Ejemplares similares